EMEA reviews policy on conflicts of interest
This article was originally published in SRA
Ongoing discussions on the European Medicines Agency’s policy on handling conflicts of interest relating to experts appointed to the scientific advisory groups that provide advice on specific types of medicinal products or treatments to the agency’s Committee for Medicinal Products for Human Use are likely to lead to a revision of the policy1.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.